RETAKLIK

Purity

99.3%

Mol. Weight

4604.2 Da

Form

Prefilled Klik-Pen

Amino Acid Sequence

Triple GIP/GLP-1/GCGR agonist

RETAKLIK contains retatrutide (LY3437943), a novel triple-acting receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Each pen contains 30mg/2.4ml (4 doses of 7.5mg). The glucagon receptor component adds thermogenic and lipolytic effects beyond what dual agonists achieve. Phase 2 clinical data demonstrated unprecedented weight reduction of up to 24% at 48 weeks. Research focuses on obesity, NASH/MAFLD, and metabolic syndrome.

Available Variants

SKU	Dosage	Price (AED)	Status
RET-1PEN	30mg	AED 850	AVAILABLE
RET-3PK	3x30mg	AED 2,295	AVAILABLE

Research Use Only. All products listed on this platform are intended solely for in-vitro research and laboratory use. They are not intended for human or animal consumption, medical diagnosis, or therapeutic application. By accessing this site, you confirm you are a qualified researcher or authorized procurement agent. No statements have been evaluated by any regulatory authority. Purchasers assume all responsibility for compliance with applicable local, national, and international regulations.